An Open-Label, Phase 1B/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, And Preliminary Efficacy Of Tak-659 In Adult Patients Wi
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
Millennium C34002
Criteria:
To Be Eligible For This Study, Patients Must Have Been Diagnosed With A Blood Cancer And Have Not Re
Keywords:
C34002 , Cancer, Hem Malignancy, Leukemia, Phase Ib/Ii
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu